Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 3/20 | 0.36 |
| ▸ | FLT4 | P35916 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4830332 | 0.83 | KDR (0.41) | KDRMAPK9MAPK10 | |
| SCHEMBL988469 | 0.80 | MAPK9 (0.45) | KDRMAPK9MAPK10FLT1FLT4 | |
| SCHEMBL4833766 | 0.75 | KDR (0.41) | KDRMAPK9MAPK10FLT1FLT4 | |
| SCHEMBL14279375 | 0.69 | ACLY (0.42) | MAPK9MAPK10PI4KAPIK3CGALOX5AP | |
| SCHEMBL25442750 | 0.69 | MAPK9 (0.56) | KDRMAPK9MAPK10FLT1FLT4 | |
| SCHEMBL28354375 | 0.69 | KDR (0.54) | KDRMAPK9MAPK10FLT1FLT4 | |
| SCHEMBL23903288 | 0.69 | MAPK9 (0.53) | KDRMAPK9MAPK10FLT1FLT4 | |
| SCHEMBL17743635 | 0.68 | MAPK9 (0.51) | KDRMAPK9MAPK10FLT1FLT4 | |
| SCHEMBL8811591 | 0.68 | PTGS2 (0.56) | MAPK9MAPK10 | |
| SCHEMBL23903552 | 0.68 | MAPK9 (0.51) | KDRMAPK9MAPK10FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | KDR 1773/4885MAPK9 49/4885MAPK10 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.